Linagliptin and Dapagliflozin: Therapeutic Applicability in T2DM with High CV Risk Dr. Kamal Kant Kohli13 Dec 2023 11:48 AM ISTType 2 Diabetes Mellitus and Cardiovascular DiseaseType 2 diabetes mellitus (T2DM) prevalence has been increasing globally, particularly in India (1)...
Evergreen Talk Series: Clinical applicability of Linagliptin in T2DM across CKD spectrum and Dapagliflozin up to CKD stage 4 MD Brand Connect1 Dec 2023 11:17 AM IST Advertisement Presenting the Evergreen Talk Series featuring Dr. Brij Mohan Makkar, a Senior Diabetologist and...
Linagliptin and Dapagliflozin: Evidence for Robust Glycemic Control and Reaping CV-CKD Benefits in T2DM (EVERGREEN) Practice Perspective Dr. Kamal Kant Kohli21 Nov 2023 12:14 PM ISTType 2 diabetes mellitus (T2DM) is growing alarmingly due to rapid urbanization, migration, aging population, and lifestyle changes; with Asia being...
Evergreen Talk Series: Clinical Benefits of Linagliptin and Dapagliflozin Combination in Type 2 Diabetes Management MD Brand Connect10 Nov 2023 11:54 AM IST Advertisement Presenting the Evergreen Talk Series featuring Dr. Brij Mohan Makkar, a...
Alkem Laboratories gets CDSCO panel nod to manufacture, market Dapagliflozin Propanediol Monohydrate, Linagliptin FDC in lower strength Dr. Divya Colin6 Nov 2023 2:09 PM ISTNew Delhi: Based on the clinical trial report presented by the drug major Alkem Laboratories of the higher strength of the fixed dose combination drug...
Linagliptin applicable across wide group of T2DM patients- Latest Indian Position Paper Dr. Nandita Mohan30 Sept 2023 11:30 AM IST As per the latest Indian position statement released in the Journal of the Association of Physicians of India, August 2023 issue, Linagliptin...
NPPA Fixes Retail Price of 51 Formulations, Details Dr. Divya Colin18 Sept 2023 6:00 PM ISTNew Delhi: Through a recent notification, the National Pharmaceutical Pricing Authority (NPPA), the Ministry of Chemicals and Fertilizers,...
Linagliptin The Evergreen Gliptin: Indian Position Paper Highlights Wide Clinical Applicabilities of Linagliptin in T2DM Dr. Kamal Kant Kohli14 Sept 2023 11:45 AM ISTA recent position paper from India has reported that Linagliptin is clinically beneficial across a wide range of patients eliminating the need for...
USV Launches Liralin Range for Diverse Group of Type 2 Diabetes Patients MD Brand Connect4 Sept 2023 1:55 PM ISTUSV Pvt. Ltd, a leading drug manufacturer in the diabetes & cardiology segment, has announced the launch of the Liralin Range for the treatment...
Lupin buys diabetes brands Ondero, Ondero Met from Boehringer Ingelheim International for Rs 235 Crore Ruchika Sharma19 Aug 2023 2:27 PM ISTMumbai: Global pharma major Lupin Limited has announced the acquisition of diabetes brands ONDERO and ONDERO MET, from Boehringer Ingelheim...
Micro Labs Gets CDSCO Panel Nod To Manufacture, Market Antidiabetic FDC Drug Dr. Divya Colin10 Jun 2023 5:45 PM ISTNew Delhi: Micro Lab has got the green signal from the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization...
Alkem Gets CDSCO Panel Nod To Manufacture, Market Linagliptin, Dapagliflozin antidiabetic FDC Dr. Divya Colin2 Jun 2023 6:00 PM ISTNew Delhi: The drug major Alkem Health Sciences has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug...
